View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 25, 2022

EMA CHMP recommends Moderna’s Covid-19 booster for adolescents

The committee’s positive opinion is based on scientific data submitted by the company, including complete safety findings.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an update to the conditional marketing authorization (CMA) to include Moderna’s 50µg booster dose of Covid-19 vaccine, Spikevax, for usage in adolescents aged 12 to 17 years.

According to the recommendation, the booster shot is indicated for use in people of this age group a minimum of three months after they receive the initial vaccine regimen.

The positive opinion from the committee is based on scientific data submitted by the company, including complete safety findings. 

Administering the 50µg booster dose a minimum of three months after the primary series is predicted to significantly boost the immune responses against the SARS-CoV-2 virus’ variants of concern, including Omicron, versus pre-boost levels.

Moderna CEO Stéphane Bancel said: “The recommendation to authorise the use of a booster dose of Spikevax in adolescents ages 12-17 is an important step to continue to protect this age group from Covid-19 and the emergence of new variants of concern. 

“We are grateful to the CHMP for their comprehensive review of our submission and look forward to an authorisation decision from the European Commission.”

Spikevax received CMA from the European Commission after EMA recommendation and is intended for active immunisation to prevent Covid-19 in people aged six years and above. 

In June, the company signed an agreement with the European Commission to amend previously agreed contractual supply schedules for the former’s Covid-19 vaccine booster product or updated booster vaccine candidate.

With this amendment, participating member States can obtain the booster vaccines later this year or earlier next year rather than the previous supply schedule in the second quarter. 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology